221 related articles for article (PubMed ID: 19367450)
1. Positron emission tomography in lung cancer.
Nomori H; Ohba Y; Yoshimoto K; Shibata H; Shiraishi K; Mori T
Gen Thorac Cardiovasc Surg; 2009 Apr; 57(4):184-91. PubMed ID: 19367450
[TBL] [Abstract][Full Text] [Related]
2. Lung cancer and positron emission tomography with fluorodeoxyglucose.
Marom EM; Erasmus JJ; Patz EF
Lung Cancer; 2000 Jun; 28(3):187-202. PubMed ID: 10812188
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic accuracy of 18F-2-deoxy-fluoro-D-glucose positron emission tomography for pN1 lymph nodes in patients with lung cancer.
Nakagawa M; Hara M; Sakurai K; Ozawa Y; Mizuno A; Tamaki T; Nishio M; Shibamoto Y
Acta Radiol; 2009 Jul; 50(6):638-44. PubMed ID: 19492198
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
5. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer.
Vanuytsel LJ; Vansteenkiste JF; Stroobants SG; De Leyn PR; De Wever W; Verbeken EK; Gatti GG; Huyskens DP; Kutcher GJ
Radiother Oncol; 2000 Jun; 55(3):317-24. PubMed ID: 10869746
[TBL] [Abstract][Full Text] [Related]
6. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
7. PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma.
Poncelet AJ; Lonneux M; Coche E; Weynand B; Noirhomme P;
Eur J Cardiothorac Surg; 2001 Sep; 20(3):468-74; discussion 474-5. PubMed ID: 11509265
[TBL] [Abstract][Full Text] [Related]
8. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer.
Kelly RF; Tran T; Holmstrom A; Murar J; Segurola RJ
Chest; 2004 Apr; 125(4):1413-23. PubMed ID: 15078754
[TBL] [Abstract][Full Text] [Related]
9. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Leuven Lung Cancer Group.
Vansteenkiste JF; Stroobants SG; De Leyn PR; Dupont PJ; Verschakelen JA; Nackaerts KL; Mortelmans LA
Chest; 1997 Dec; 112(6):1480-6. PubMed ID: 9404742
[TBL] [Abstract][Full Text] [Related]
10. Role of FDG-PET in the diagnosis and management of lung cancer.
Oyen WJ; Bussink J; Verhagen AF; Corstens FH; Bootsma GP
Expert Rev Anticancer Ther; 2004 Aug; 4(4):561-7. PubMed ID: 15270660
[TBL] [Abstract][Full Text] [Related]
11. Role of
Delgado Bolton RC; Calapaquí-Terán AK; Giammarile F; Rubello D
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(4):229-233. PubMed ID: 31202725
[TBL] [Abstract][Full Text] [Related]
12. Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer.
Gayed I; Vu T; Johnson M; Macapinlac H; Podoloff D
Mol Imaging Biol; 2003; 5(1):26-31. PubMed ID: 14499159
[TBL] [Abstract][Full Text] [Related]
13. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
Aquino SL; Fischman AJ
Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
[TBL] [Abstract][Full Text] [Related]
14. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.
Farrell MA; McAdams HP; Herndon JE; Patz EF
Radiology; 2000 Jun; 215(3):886-90. PubMed ID: 10831716
[TBL] [Abstract][Full Text] [Related]
15. FDG PET: advantages for staging the mediastinum?
Franzius C
Lung Cancer; 2004 Aug; 45 Suppl 2():S69-74. PubMed ID: 15552784
[TBL] [Abstract][Full Text] [Related]
16. Improved radiologic staging of lung cancer with 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography and computed tomography registration.
Aquino SL; Asmuth JC; Alpert NM; Halpern EF; Fischman AJ
J Comput Assist Tomogr; 2003; 27(4):479-84. PubMed ID: 12886128
[TBL] [Abstract][Full Text] [Related]
17. Present and future roles of FDG-PET/CT imaging in the management of lung cancer.
Kitajima K; Doi H; Kanda T; Yamane T; Tsujikawa T; Kaida H; Tamaki Y; Kuribayashi K
Jpn J Radiol; 2016 Jun; 34(6):387-99. PubMed ID: 27121156
[TBL] [Abstract][Full Text] [Related]
18. Value of FDG-PET in the management of non-small cell lung cancer.
Stroobants S; Verschakelen J; Vansteenkiste J
Eur J Radiol; 2003 Jan; 45(1):49-59. PubMed ID: 12499064
[TBL] [Abstract][Full Text] [Related]
19. Emerging role of PET in the diagnosis and staging of lung cancer.
Coates G; Skehan SJ
Can Respir J; 1999; 6(2):145-52. PubMed ID: 10322097
[TBL] [Abstract][Full Text] [Related]
20. Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer.
Dooms C; van Baardwijk A; Verbeken E; van Suylen RJ; Stroobants S; De Ruysscher D; Vansteenkiste J
J Thorac Oncol; 2009 Jul; 4(7):822-8. PubMed ID: 19487964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
